Halozyme dips after ViroPharma ends subcutaneous Cinryze study
This article was originally published in Scrip
Executive Summary
Halozyme Therapeutics closed down 14% at $7.32 per share on 1 August after ViroPharma ended a Phase II clinical trial for a subcutaneous formulation of Cinryze that contains Halozyme's recombinant human hyaluronidase (rHuPH20) enzyme after several patients developed non-neutralizing anti-rHuPH20 antibodies.